These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 701299)

  • 21. Sustained release phenylpropanolamine hydrochloride from ATO 888 matrix.
    Perez MA; Ghaly ES; Marti A
    P R Health Sci J; 1993 Dec; 12(4):263-7. PubMed ID: 8140204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two galactomannans and scleroglucan as matrices for drug delivery: preparation and release studies.
    Coviello T; Alhaique F; Dorigo A; Matricardi P; Grassi M
    Eur J Pharm Biopharm; 2007 May; 66(2):200-9. PubMed ID: 17156985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Floating matrix dosage form for phenoporlamine hydrochloride based on gas forming agent: in vitro and in vivo evaluation in healthy volunteers.
    Xu X; Sun M; Zhi F; Hu Y
    Int J Pharm; 2006 Mar; 310(1-2):139-45. PubMed ID: 16413710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Controlled release of theophylline from inert matrices: effect of channeling material on release rate.
    Ghaly ES; Malavé MI; Rivera WJ; Martí A
    P R Health Sci J; 1993 Dec; 12(4):255-8. PubMed ID: 8140202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in mechanistic understanding of release rate control mechanisms of extended-release hydrophilic matrix tablets.
    Timmins P; Desai D; Chen W; Wray P; Brown J; Hanley S
    Ther Deliv; 2016 Aug; 7(8):553-72. PubMed ID: 27444495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The effects of some factors on the rate of the in vitro release of active substances from depot tablets. 3. The release rate of tetracycline hydrochloride from layered and nonlayered depot tablets].
    Michailova D; Naplatanova D; Slavtschev P; Tomassini L
    Pharmazie; 1978 Apr; 33(4):212-6. PubMed ID: 674317
    [No Abstract]   [Full Text] [Related]  

  • 27. pH- and flow-rate-independent release of drug from uncoated slow-release tablets.
    Jambhekar SS; Cobby J
    J Pharm Sci; 1985 Sep; 74(9):991-4. PubMed ID: 4067855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of internal structure on kinetics of drug release from wax matrix tablets.
    Ishino R; Yoshino H; Hirikawa Y; Noda K
    Chem Pharm Bull (Tokyo); 1990 Dec; 38(12):3440-5. PubMed ID: 2092942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A method to optimize the design parameters of sustained release preparations.
    Cadorniga R; Frutos G; Martin PJ
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():385-8. PubMed ID: 1820912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modeling the modified drug release from curved shape drug delivery systems - Dome Matrix®.
    Caccavo D; Barba AA; d'Amore M; De Piano R; Lamberti G; Rossi A; Colombo P
    Eur J Pharm Biopharm; 2017 Dec; 121():24-31. PubMed ID: 28917534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Application of mathematical modeling in sustained release delivery systems.
    Grassi M; Grassi G
    Expert Opin Drug Deliv; 2014 Aug; 11(8):1299-321. PubMed ID: 24938598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Finite element analysis of the release of slowly dissolving drugs from cylindrical matrix systems.
    Frenning G; Brohede U; Strømme M
    J Control Release; 2005 Oct; 107(2):320-9. PubMed ID: 16081182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elastic-plastic contact law for simulation of tablet crushing using the biharmonic equation.
    Ahmat N; Ugail H; González Castro G
    Int J Pharm; 2012 May; 427(2):170-6. PubMed ID: 22326300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The coefficient of rolling resistance (CoRR) of some pharmaceutical tablets.
    Ketterhagen WR; Bharadwaj R; Hancock BC
    Int J Pharm; 2010 Jun; 392(1-2):107-10. PubMed ID: 20307633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Release from or through a wax matrix system. I. Basic release properties of the wax matrix system.
    Yonezawa Y; Ishida S; Sunada H
    Chem Pharm Bull (Tokyo); 2001 Nov; 49(11):1448-51. PubMed ID: 11724236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Finite element analysis of diffusional drug release from complex matrix systems. II. Factors influencing release kinetics.
    Wu XY; Zhou Y
    J Control Release; 1998 Jan; 51(1):57-71. PubMed ID: 9685904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A METHOD FOR RELEASE RATE DETERMINATION FROM SUSTAINED-RELEASE TABLETS.
    SJOEGREN J; ERVIK M
    Acta Pharm Suec; 1964 Dec; 1():219-26. PubMed ID: 14246018
    [No Abstract]   [Full Text] [Related]  

  • 38. [Problems in the optimal use of celluloses as adjuvants in tablet composition. 1. Motivation and structure of general and special experimental plans].
    Moldenhauer H; Loh HJ; Kala H
    Pharmazie; 1978 Jan; 33(1):69-71. PubMed ID: 674280
    [No Abstract]   [Full Text] [Related]  

  • 39. Influence of shape factors on kinetics of drug release from matrix tablets. I. Theoretical.
    Cobby J; Mayersohn M; Walker GC
    J Pharm Sci; 1974 May; 63(5):725-32. PubMed ID: 4829995
    [No Abstract]   [Full Text] [Related]  

  • 40. MATHEMATICAL TREATMENT OF ORAL SUSTAINED RELEASE DRUG FORMULATIONS.
    ROWLAND M; BECKETT AH
    J Pharm Pharmacol; 1964 Dec; 16():SUPPL:156-62T. PubMed ID: 14265931
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.